JAGSONPAL PHARMACEUTICALS

31.6 +0.15 (+0.48%) Sell

JAGSNPHARM shows sign of weakness as investors do cost averaging

15 min read

JAGSONPAL PHARMACEUTICALS managed to outperform the broader market on Wednesday. It surged by +0.48% to close at 31.6. On a day when the overall market breadth was 70%, it closed higher than 77% of the market. In comparison, the benchmark NIFTY-50 index closed today at -0.0084%.

[Themes containing JAGSNPHARM]

JAGSNPHARM is currently in a bearish trend. The previous short signal in JAGSNPHARM has not been profitable for investors in general. If you are short on JAGSNPHARM at current levels please make sure that your allocation is limited and that your portfolio is well diversified.

Trend

JAGSNPHARM has been outperforming the NIFTY-50 index in recent time. It showed significant underperformance (compared to the NIFTY-50 index) from 5 Jan, 2016 to 23 Jul, 2018. Over the last 3 years and 1 month, JAGSNPHARM underperformed the NIFTY-50 index on 55% days.

JAGSNPHARM returned losses on 56% days in the last three months. During this time, it delivered on average +0.19% per day. It delivered it's best daily return of +7.76%, during this period, on Wednesday, 14 Nov, 2018. The longest stort-term trend during this period was 4 losing days, which started on 15 Nov, 2018 and ended on 20 Nov, 2018. This bearish trend lost -5.0% of investor capital.

During the last year JAGSNPHARM had 7 profitable months and 5 loss making months. JAGSNPHARM returned profits in more months than NIFTY-50 index. JAGSNPHARM was also a more risky investment than NIFTY-50 index as it's worst month in the last year, Mar 2018, returned -13.55% compared to -6.42% returned by NIFTY-50 index in Sep 2018. JAGSNPHARM had a longer winning streak of profitable months than NIFTY-50 index. It went up in 4 straight months (from Oct 2018 to Jan 2019) during which period it delivered +24.57%. It is interesting to note that both JAGSNPHARM and NIFTY-50 index significantly outperform during months when quarterly/annual results are announced.

Money is not the only answer, but it makes a difference.
-- Barack Obama

JAGSNPHARM is currently seeing overall increase in volatility. In comparison, the NIFTY-50 index is seeing decrease in volatility. During the last three months, there was a significant surge in JAGSNPHARM's volatility from 29 Oct, 2018 to 13 Dec, 2018. While there was a significant fall in the NIFTY-50 index's volatility from 31 Oct, 2018 to 5 Dec, 2018.

Advanced/professional short-term investors should note that JAGSNPHARM has significant negative skewness in it's return distribution. This indicates that JAGSNPHARM is very risky for short-term investment and can significantly underperform for long durations.

NIFTY-50 index has more chance of extreme outcomes than JAGSNPHARM. Therefore, NIFTY-50 must receive a lower allocation than JAGSNPHARM in your portfolio. NIFTY-50 index usually has shorter drawdown period than JAGSNPHARM.

Based on your interest in JAGSNPHARM you may find it interesting to know that GKWLIMITED, ICIL and INDORAMA have all performed similar to JAGSNPHARM and qualify as alternative investment candidates that must be evaluated for diversification.

Want to improve your Portfolio's performance?

Spotalpha's Portfolio optimizer is all you need to improve your returns and reduce your risk.
Optimize Portfolio NOW
If you liked what you read here ...

... we have a small favour to ask. Help us bring the power of algorithmic trading strategies to individual investors.

All content in this article was automatically generated by algorithms. This ensures that there are no human biases in the analysis provided. This approach to investing is not new and has been around for more than three decades. Yet, it has been available to only the most affluent or elite investors leaving individual investors to trade on emotions (such as fear and greed), intuition and poor analysis from third-parties. We want to change this.

We want to empower investors with all the tools and analysis required by them to make a rational investment decision.

If you found Spotalpha useful, consider making a contribution. For as little as $5 you can support our efforts and it takes less than a minute. Thank you. Contribute
Share with friends   WhatsApp   Facebook   Twitter